IgG4 Blocking Antibody Induction in Transplant Rejection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
In transplant recipients, existing methods fail to effectively manage donor-specific human leukocyte antigen (HLA) antibodies, particularly IgG subclasses G1 and G3, which contribute to rejection, while IgG subclass G4, with its blocking antibody properties, is beneficial but challenging to induce and maintain.
Innovation Solution
The method involves administering HLA antigens or modified cells to promote the production of IgG4 blocking antibodies, using desensitization protocols, and monitoring IgG subclass levels to increase G4 levels, which can be achieved through indirect or direct approaches, including antigen administration or genetic modification of tissue cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If desensitization protocols are used to induce IgG4 blocking antibodies, then the blocking antibody levels increase, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent applies preliminary action by administering HLA antigens to the recipient before transplantation to pre-induce IgG4 blocking antibodies. This preparatory step creates a protective immune environment in advance, reducing the risk of rejection during and after transplantation. The method involves multiple pre-transplant infusions of donor-specific HLA antigens to establish blocking antibody levels before the actual transplant procedure.
Solution Approach 2:
The patent utilizes parameter changes by monitoring and manipulating the levels of IgG subclasses, specifically aiming to increase IgG4 blocking antibody levels while managing other IgG subclasses. The treatment protocol adjusts dosing intervals and antigen doses based on measured antibody levels, dynamically changing treatment parameters to achieve optimal blocking antibody production.
2Reliability
If HLA antigens are administered to promote IgG4 production, then rejection risk decreases, but the number of treatment steps increases
Solution Approach 1:
The patent implements preliminary action by administering HLA antigens in a structured pre-transplant schedule (e.g., weeks -2, -1, 0) to establish blocking antibody levels before transplantation. This advance preparation reduces the immunological risk at the critical transplant moment, allowing the procedure to proceed with lower rejection risk despite the multiple treatment steps required.
Solution Approach 2:
The patent employs feedback mechanisms by monitoring IgG subclass levels throughout treatment and using this information to adjust subsequent dosing decisions. Laboratory measurements of blocking antibody levels guide whether to continue, modify, or discontinue antigen administration, creating a closed-loop system that adapts to the patient's immune response.
3Object-affected harmful factors
If IgG4 blocking antibodies are increased, then complement fixation is inhibited, but the difficulty of maintaining stable levels increases
Solution Approach 1:
The patent applies periodic action by administering HLA antigens at regular intervals (e.g., weekly or biweekly infusions) to maintain sustained production of IgG4 blocking antibodies. This rhythmic stimulation of the immune system ensures continuous antibody production rather than a single bolus response, helping to maintain stable blocking levels over the treatment period and beyond.
Solution Approach 2:
The patent implements continuity of useful action by establishing a prolonged treatment regimen that maintains blocking antibody production throughout the critical early post-transplant period. The protocol extends antigen administration well into the post-transplant phase to ensure continuous protective antibody levels during the period when rejection risk is highest, rather than stopping immediately after transplantation.
Data Source
AI summary
A method can include determining a donor-specific human leukocyte antigen of a tissue transplant recipient; determining a ratio of the tissue transplant recipient for a level of an immunoglobulin G subclass 4 antibody (G4) for the antigen with respect to a level of another immunoglobulin G subclass antibody for the antigen; and, based on the ratio, deciding to administer an amount of the G4 to the tissue transplant recipient.